Tom Roberts, CEO of San Antonio, Texas-based startup Invictus Medical discusses the company's approach to preventing the cranial deformation plagiocephaly, also known as flattening of the skull, that affects up to 30% of newborns.
Cardiologist Dr. Darrel Francis finds himself attempting once again to drag the conversation back from the edge of hyperbole as the market reacts to the lackluster outcome of Medtronic's highly anticipated Symplicity HTN-3 trial of renal denervation in treatment of hypertension.
Neurosurgeon Dr. Philip Starr tells MassDevice.com about Medtronic's new Activa PC+S brain monitoring, recording and stimulating implant and its potential for treating neurological and psychiatric disease.
Medtech titan Medtronic says that it's not involved with research on an orgasm-inducing neurostimulation system, despite reports to the contrary.
Medical device industry giant Medtronic (NYSE:MDT) told MassDevice.com today that despite reports of the company's participation in upcoming studies, Medtronic is not involved with research on an implantable neurostimulator designed for treatment of sexual dysfunction.
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com's coverage highlights our 3 biggest and most influential stories from the day's news to make sure you're up to date on the headlines that continue to shape the medical device industry.
FDA's official blog brought to you from FDA's senior leadership and staff stationed at home and abroad - sharing news, background, announcements and other information about the work done at the FDA on behalf of the American public.
By: William Tootle
A few days ago, President Obama released his Fiscal Year 2015 Budget Message to Congress, which included a high-level summary of his proposed funding for the FDA. Today the White House is out with the full budget, complete with all of the nitty gritty details.
Analogic is on track with layoffs and facilities closures announced last year, but ALOG shares dive after the company reports disappointing earnings for its 2nd quarter and projects flat progress for the year ahead.